Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Sorafenib in Advanced Melanoma
NCT00387751Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- Sep 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib, bevacizumab in Malignant Melanoma (MM), sponsored by National Cancer Institute. Started Aug 2006; status: completed.
02
Drugs
sorafenibbevacizumab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00387751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387751.